Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways (2022)

Peer-Reviewed Study · Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; et al. · June 2022

Lu H et al., 2022-06: Hepatocellular carcinoma study reporting that ivermectin inhibits HCC growth and metastasis, targets stem-cell markers and mTOR/STAT3 signalling, and synergises with sorafenib in vitro and in SNU-182 mouse xenografts. RETRACTED in February 2026 (notice PMID 41689298, DOI 10.1002/prp2.70222).

SNU-182 cells were inoculated into the flanks of mice and treated with either oral ivermectin at 10 mg/kg once daily or vehicle.

n/a (HTML full text, figure legend)

Lu H et al., 2022-06: Hepatocellular carcinoma study reporting that ivermectin inhibits HCC growth and metastasis, targets stem-cell markers and mTOR/STAT3 signalling, and synergises with sorafenib in vitro and in SNU-182 mouse xenografts. RETRACTED in February 2026 (notice PMID 41689298, DOI 10.1002/prp2.70222). Study type: HCC cell lines + SNU-182 mouse xenograft. N: 10-12 mice per group. Country: China (Yangtze University, Jingzhou). Dose: oral ivermectin 5 or 10 mg/kg once daily; comparator: vehicle (0.5% methylcellulose) and sorafenib alone. Funder/COI: not stated in the PubMed record. Excerpt is a figure-legend record field rather than prose. STATUS: RETRACTED. PubMed marks this record ‘Retracted Publication’ with RetractionIn PMID 41689298 (Pharmacol Res Perspect 2026 Feb;14(1):e70222, DOI 10.1002/prp2.70222), February 2026. Grounds as stated in the notice: retracted by agreement of the authors, the Editor-in-Chief, the British Pharmacological Society and Wiley after concerns that the corresponding author was not personally involved in the submission, did not sign the Open Access Agreement and did not review or approve the final manuscript; the investigation also found duplication of several images and figures from previously published articles. Study type: animal.